RESHAPING THE FUTURE OF DRUG DISCOVERY
Our mission is to improve lives by reducing societal disease burden
We utilize our novel proprietary in-silico platform along with established in vitro and in vivo assays to design and discover small molecule compounds that interrupt proteins in disease pathways. Designed through uniting AI, quantum chemistry and computer vision, these compounds interrupt proteins allosterically, directly, or formatively.
We are pursuing treatments for prevalent neurodegenerative, inflammatory and infectious disease conditions by focusing on interrupting aberrant, overexpressed, or pathogenic proteins in established pathways.
Bleeding-Edge Technology
Interrupt Proteins Like Never Before
Our novel in silico quasi quantum calculation methodology combined with a unique computation-first approach and diverse, purpose-driven team of experts delivers unparalleled results. Merging traditionally disparate scientific disciplines and utilizing cutting-edge technology and methodologies allows us to efficiently iterate and refine drug candidates, leading to higher success rates and a faster time-to-societal-impact for our clients. Our leading approach and expertise have resulted in a proven track record of success, and we are dedicated to bringing advanced science driven therapeutics to patients.
Drug Discovery Process
Learn how our unique drug discovery process to addresses the burden of disease on society. For more detailed information click here.
1
Predict and construct organic compounds that can directly or allosterically interrupt proteins in biological pathways using in silico methodology.
3
Iterate and optimize compounds using derivative molecules based on in vitro results.
.jpg)
